

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stanley Wiegand et al.

Serial No.: to be assigned

Group: Not Yet Assigned

Filing Date: Concurrently herewith

Examiner: Not Yet Assigned

Title: Methods of Identifying Modulators of NMUR2-Mediated Activity

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references, which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:


- [X]** Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Att. Docket No.: REG 980A
USSN: to be assigned
File Date: Concurrently herewith
Information Disclosure Statement

Fees

There is no fee required for the filing of this Information Disclosure Statement.
In the event there is a fee inadvertently omitted, Applicants hereby authorizes the fee to
be charge to Deposit Account number 18-0650.

Respectfully submitted



Valeta Gregg
Reg. No. 35,127
Attorney for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 980A
Serial No. : to be assigned
Applicant: : Stanley J. Wiegand et al.
Date Filed : Concurrently herewith
For : METHODS OF IDENTIFYING
MODULTORS OF NMUR2-MEDIATED
ACTIVITY

Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	6,461,836	Oct. 8, 2002	Elshourbagy et al.	_____	Apr. 10, 2000

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation</u> <u>Yes</u> <u>No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner
Initials

_____ Raddatz, et al., J. Biol. Chem. Vol. 275, No. 42, pp. 32452-32459
 (2000)

_____ Howard, et al., Nature, vol. 406, pp. 71-74, (2000)

_____ Shan et al., J. Biol. Chem., Vol. 275, No. 50, pp 39482-39486, (2000)

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in
 conformance with MPEP 609; draw line through citation if
 not in conformance and not considered. Include copy of this
 form with next communication to applicant.

Respectfully submitted,

By: 
Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400